Uncategorized

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and more aim to deliver the next wave of progress with near-term data and regulatory milestones.

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this month the company has secured an approval for AstraZeneca-partnered Dato-DXd, to be marketed as Datroway.

Brenner, who worked in the FDA’s Center for Devices and Radiological Health, will take the helm of the agency until a new leader is confirmed.

Brenner, who worked in the FDA’s Center for Devices and Radiological Health, will take the helm of the agency until a new leader is confirmed.

The surgical robot leader is watching developments under the new administration but has not included any tariff impact in its financial forecast.

The Washington-based health system is launching an Office of Transformation to oversee the deployment of technology, including artificial intelligence, across the organization.

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health agencies, among other moves that have sent waves through the biopharma industry.

Doug Collins expressed interest in restarting EHR deployments sooner than planned. One lawmaker called the years-long project a “bipartisan, multi-administration disaster.”

UnitedHealthcare has a new chief executive seven weeks after former CEO Brian Thompson was shot and killed in New York City.

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA nod in September 2014.